— Know what they know.
Not Investment Advice

ARVN NASDAQ

Arvinas, Inc.
1W: -3.4% 1M: -14.4% 3M: -24.1% YTD: -20.7% 1Y: +37.0% 3Y: -61.0% 5Y: -86.4%
$9.09
-0.01 (-0.11%)
 
Weekly Expected Move ±6.0%
$8 $9 $9 $10 $10
NASDAQ · Healthcare · Biotechnology · Alpha Radar Strong Sell · Power 29 · $586.5M mcap · 56M float · 1.65% daily turnover · Short 38% of daily vol

Revenue Segmentation

By Product / Service

Revenue by Segment (5-Year Trend)

Income Trends

Revenue
$263M -0.3% ▼
5Y CAGR: +58.9%
Gross Profit
$257M -2.3% ▼
5Y CAGR: +58.3%
Operating Income
-$115M +54.1% ▲
Net Income
-$81M +59.4% ▲
EPS (Diluted)
$-1.28 +53.8% ▲
EBITDA
-$75M +69.1% ▲

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
Revenue$54M$131M$78M$263M$263M
YoY Growth+106.9%+145.1%-40.3%+235.5%-0.3%
Cost of Revenue$0$0$0$0$5M
Gross Profit$54M$131M$78M$263M$257M
Gross Margin100.0%100.0%100.0%100.0%98.0%
R&D Expenses$180M$315M$380M$348M$283M
SG&A Expenses$62M$80M$100M$165M$89M
Operating Expenses$242M$395M$480M$514M$372M
Operating Income-$188M-$263M-$402M-$250M-$115M
Operating Margin-351.5%-200.3%-511.5%-95.0%-43.8%
Interest Expense$100K$0$0$0$0
Income Before Tax-$191M-$262M-$366M-$198M-$80M
Tax Expense$0$21M$900K$600K$300K
Net Income-$191M-$282M-$367M-$199M-$81M
Net Margin-356.3%-215.0%-467.9%-75.5%-30.8%
EPS (Diluted)$-3.82$-5.31$-6.62$-2.77$-1.28
EBITDA-$182M-$255M-$395M-$244M-$75M
Shares Outstanding50M53M56M72M65M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms